329 related articles for article (PubMed ID: 33262028)
1. Bacillus Calmette-Guerin (BCG): Its fight against pathogens and cancer.
Sfakianos JP; Salome B; Daza J; Farkas A; Bhardwaj N; Horowitz A
Urol Oncol; 2021 Feb; 39(2):121-129. PubMed ID: 33262028
[TBL] [Abstract][Full Text] [Related]
2. Bacillus Calmette-Guérin failure in patients with non-muscle-invasive urothelial carcinoma of the bladder may be due to the urologist's failure to detect urothelial carcinoma of the upper urinary tract and urethra.
Giannarini G; Birkhäuser FD; Recker F; Thalmann GN; Studer UE
Eur Urol; 2014 Apr; 65(4):825-31. PubMed ID: 24144432
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of bacillus Calmette-Guérin Strains for Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Network Meta-Analysis.
Boehm BE; Cornell JE; Wang H; Mukherjee N; Oppenheimer JS; Svatek RS
J Urol; 2017 Sep; 198(3):503-510. PubMed ID: 28286068
[TBL] [Abstract][Full Text] [Related]
4. History of bacillus Calmette-Guerin and bladder cancer: an immunotherapy success story.
Herr HW; Morales A
J Urol; 2008 Jan; 179(1):53-6. PubMed ID: 17997439
[TBL] [Abstract][Full Text] [Related]
5. Intravesical bacillus Calmette-Guérin efficiently reduces p70S6K1 but not 4E-BP1 phosphorylation in nonmuscle invasive bladder cancer.
Ferrari KL; de Camargo JA; Rocha GZ; Carvalheira JB; Saad MJ; Billis A; Reis LO
J Urol; 2015 Feb; 193(2):682-9. PubMed ID: 25200808
[TBL] [Abstract][Full Text] [Related]
6. Systemic versus localized Bacillus Calmette Guérin immunotherapy of bladder cancer promotes an anti-tumoral microenvironment: Novel role of trained immunity.
Atallah A; Grossman A; Nauman RW; Paré JF; Khan A; Siemens DR; Cotechini T; Graham CH
Int J Cancer; 2024 Jul; 155(2):352-364. PubMed ID: 38483404
[TBL] [Abstract][Full Text] [Related]
7. Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign.
Li R; Metcalfe MJ; Tabayoyong WB; Guo CC; Nogueras González GM; Navai N; Grossman HB; Dinney CP; Kamat AM
Eur Urol Oncol; 2019 May; 2(3):286-293. PubMed ID: 31200843
[TBL] [Abstract][Full Text] [Related]
8. Unraveling the Mechanism of the Antitumor Activity of Bacillus Calmette-Guérin.
Li R; Gilbert SM; Kamat AM
Eur Urol; 2021 Jul; 80(1):1-3. PubMed ID: 32861573
[TBL] [Abstract][Full Text] [Related]
9. Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer.
Böhle A; Brandau S
J Urol; 2003 Sep; 170(3):964-9. PubMed ID: 12913751
[TBL] [Abstract][Full Text] [Related]
10. Insignificant role of bacillus Calmette-Guérin maintenance therapy after complete transurethral resection of bladder tumor for intermediate- and high-risk non-muscle-invasive bladder cancer: Results from a randomized trial.
Nakai Y; Anai S; Tanaka N; Chihara Y; Haramoto M; Otani T; Nakagawa Y; Hirao Y; Konishi N; Fujimoto K
Int J Urol; 2016 Oct; 23(10):854-860. PubMed ID: 27416975
[TBL] [Abstract][Full Text] [Related]
11. Critical shortage in BCG immunotherapy: How did we get here and where will it take us?
Harvey M; Chislett B; Perera M; Lawrentschuk N; Bolton D; Jack G
Urol Oncol; 2022 Jan; 40(1):1-3. PubMed ID: 34750053
[TBL] [Abstract][Full Text] [Related]
12. Intravesical instillation therapy with bacillus Calmette-Guérin for superficial bladder cancer: study of the mechanism of bacillus Calmette-Guérin immunotherapy.
Shintani Y; Sawada Y; Inagaki T; Kohjimoto Y; Uekado Y; Shinka T
Int J Urol; 2007 Feb; 14(2):140-6. PubMed ID: 17302571
[TBL] [Abstract][Full Text] [Related]
13. Bacillus Calmette-Guérin immunotherapy for genitourinary cancer.
Gandhi NM; Morales A; Lamm DL
BJU Int; 2013 Aug; 112(3):288-97. PubMed ID: 23517232
[TBL] [Abstract][Full Text] [Related]
14. Can early single dose instillation of epirubicin improve bacillus Calmette-Guerin efficacy in patients with nonmuscle invasive high risk bladder cancer? Results from a prospective, randomized, double-blind controlled study.
Cai T; Nesi G; Tinacci G; Zini E; Mondaini N; Boddi V; Mazzoli S; Bartoletti R
J Urol; 2008 Jul; 180(1):110-5. PubMed ID: 18485394
[TBL] [Abstract][Full Text] [Related]
15. Autophagy controls BCG-induced trained immunity and the response to intravesical BCG therapy for bladder cancer.
Buffen K; Oosting M; Quintin J; Ng A; Kleinnijenhuis J; Kumar V; van de Vosse E; Wijmenga C; van Crevel R; Oosterwijk E; Grotenhuis AJ; Vermeulen SH; Kiemeney LA; van de Veerdonk FL; Chamilos G; Xavier RJ; van der Meer JW; Netea MG; Joosten LA
PLoS Pathog; 2014 Oct; 10(10):e1004485. PubMed ID: 25356988
[TBL] [Abstract][Full Text] [Related]
16. Predicting response to bacillus Calmette-Guérin (BCG) in patients with carcinoma in situ of the bladder.
Nunez-Nateras R; Castle EP; Protheroe CA; Stanton ML; Ocal TI; Ferrigni EN; Ochkur SI; Jacobsen EA; Hou YX; Andrews PE; Colby TV; Lee NA; Lee JJ
Urol Oncol; 2014 Jan; 32(1):45.e23-30. PubMed ID: 24055426
[TBL] [Abstract][Full Text] [Related]
17. Reduction of Bladder Volume after BCG Immunotherapy.
Yang C; Lv Z; Li Y
Urol Int; 2021; 105(1-2):155-158. PubMed ID: 32882690
[TBL] [Abstract][Full Text] [Related]
18. Can we treat bladder cancer with intravesical Bacillus Calmette-Guerin in patients with prior tuberculosis infection? A population-based cohort study.
Hsu CW; Chiu YC; Hu HY; Fan YH; Hong SC; Cheng WM
BMC Urol; 2020 Jul; 20(1):91. PubMed ID: 32641099
[TBL] [Abstract][Full Text] [Related]
19. Randomized Controlled Study of the Efficacy, Safety and Quality of Life with Low Dose bacillus Calmette-Guérin Instillation Therapy for Nonmuscle Invasive Bladder Cancer.
Yokomizo A; Kanimoto Y; Okamura T; Ozono S; Koga H; Iwamura M; Tanaka H; Takahashi S; Tsushima T; Kanayama HO; Akaza H; Shinohara N; Mugiya S; Nomata K; Nakamura T; Naito S
J Urol; 2016 Jan; 195(1):41-6. PubMed ID: 26307162
[TBL] [Abstract][Full Text] [Related]
20. Biology of BCG response in non-muscle invasive bladder cancer - 2021 IBCN Updates Part III.
Reike MJ; Ingersoll MA; Müller DC; Zuiverloon TCM; Strandgaard T; Kamat AM; Williams SB; Seiler R; Todenhöfer T; Dyrskjøt L; Nawroth R; Goebell P; Schmitz-Dräger B; Sfakianos JP; Meeks J; Horowitz A; Black PC
Urol Oncol; 2023 May; 41(5):211-218. PubMed ID: 36266219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
